The MYSTIC [31] trial is a phase III trial of patients with lung cancer that uses the same strategy but different drugs, such as Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4) as first-line therapy. Here, CTLA4 is linked to lung cancer.